New hope for tough-to-treat pancreatic cancer? early trial tests combo approach
NCT ID NCT05417386
First seen Nov 18, 2025 · Last updated May 14, 2026 · Updated 16 times
Summary
This early-phase study tested whether adding the experimental drug NIS793 to standard chemotherapy (FOLFIRINOX) is safe and effective for people with metastatic pancreatic cancer. Only 4 participants were enrolled before the study was stopped. The goal was to find the right dose and see if the combo could help shrink tumors enough for surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREAS CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.